- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Coronary Vasospasm.
Displaying page 1 of 1.
EudraCT Number: 2006-003116-22 | Sponsor Protocol Number: RBK091 | Start Date*: 2006-12-21 |
Sponsor Name:Prof. Sechtem, Department of Cardiology, Robert Bosch Hospital | ||
Full Title: Application of Sildenafil in patients with documented coronary vasospasm in order to explore the pathophysiology of coronary vasospasm and the therapeutic effects of Sildenafil in patients sufferin... | ||
Medical condition: Coronary vasospasm is an abrupt severe vasoconstriction of coronary arteries leading to myocardial ischemia and angina pectoris. The reason for the occurrence of coronary spasm and the cellular mec... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002623-42 | Sponsor Protocol Number: 66623 | Start Date*: 2019-02-18 | |||||||||||
Sponsor Name:Academic Medical Center | |||||||||||||
Full Title: Vasospastic angina treatment by Endothelin Receptor Antagonism; a proof of concept study | |||||||||||||
Medical condition: Vasospastic angina, i.e. epicardial vasospasm or microvascular coronary dysfunction. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002646-36 | Sponsor Protocol Number: B1481022 | Start Date*: 2014-02-14 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, ny 10017 | |||||||||||||
Full Title: PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF M... | |||||||||||||
Medical condition: atherosclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) SE (Completed) SK (Prematurely Ended) ES (Completed) IT (Completed) BE (Prematurely Ended) DK (Completed) PL (Prematurely Ended) IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002795-41 | Sponsor Protocol Number: B1481038 | Start Date*: 2014-02-14 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, ny 10017 | |||||||||||||
Full Title: PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF M... | |||||||||||||
Medical condition: atherosclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Prematurely Ended) FI (Prematurely Ended) IT (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) SK (Prematurely Ended) ES (Completed) BE (Prematurely Ended) DK (Completed) SE (Completed) IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.